Corporate

  • Jan. 21, 2015 biOasis Announces the Release of an Analyst Report

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V: BTI)(OTCQX: BIOAF)(the “Company”) wishes to announce the release of an analyst report (the “Report”) providing a synopsis of the Company. Mr. Jim Darcel, www.jrstocks.com, prepared the Report. The Company cautions its investors, shareholders and other parties that any opinions, estimates or forecasts regarding the Company’s performance made by… Read more »

  • Oct. 8, 2014 biOasis Engages Willow Tree Group to Assist with Global Business Development Activities

    Vancouver, British Columbia–(Business Wire)– biOasis Technologies, Inc.(OTCQX:BIOAF; TSX.V:BTI), the pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-­brain barrier (“BBB”), engages Willow Tree Capital Group of Toronto, Canada. Willow Tree’s full service team of healthcare, scientific and business specialists provides a comprehensive suite of business development services to life science companies… Read more »

  • Jun. 21, 2014 biOasis Appoints New Chief Financial Officer and Corporate Secretary

    Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (OTCQX:BIOAF) (TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, announces the appointment of Ms. Judi Dalling as its Chief Financial Officer and Corporate Secretary effective immediately. Ms. Dalling is an experienced professional, a graduate of The University of… Read more »

  • Jun. 17, 2014 biOasis Enters Investor Relations Agreement with Gale Capital Corporation

    Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) (OTCQX: BIOAF) (the “Company”) is pleased to announce that is has retained Gale Capital Corporation (“Gale Capital”) effective June 15, 2014 to assist the Company with its shareholder relations activities and investor awareness program. Gale Capital will help by cultivating productive dialogue with analysts, brokers, potential investors… Read more »

  • Mar. 27, 2014 biOasis Receives Patent Allowances for Lysosomal Storage Disease Therapeutic in Europe and Canada

    Key Patent Allowances Represent Major Step Toward International Exclusivity for its LSD- Therapeutic in the $2 Billion LSD Market

  • Mar. 17, 2014 biOasis Enters into a License Agreement with MedImmune for Second Generation Versions of biOasis’s Transcend

    Vancouver, British Columbia–(Business Wire)– biOasis Technologies, Inc. (OTCQX:BIOAF; TSXV:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has signed an evaluation agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Under the terms of the agreement, MedImmune will evaluate the therapeutic effect of… Read more »

  • Oct. 2, 2013 biOasis Engages Liolios Group to Lead New Investor Relations Program

    Vancouver, British Columbia–(Business Wire)– biOasis Technologies, Inc. (TSX.V: BTI, OTCBB: BIOAF), a pioneer in the delivery of therapeutics across the blood-brand barrier, has engaged Liolios Group to lead a new investor relations and financial communications campaign. “Over the course of the last 12 months, leading independent researchers have demonstrated how our Transcend™ technology is able… Read more »

  • Aug. 8, 2013 biOasis Technologies Inc. Announces Notice of Allowance for Key Lysosomal Storage Disease Patent From the US Patent and Trademark Office

    Vancouver, British Columbia–(Business Wire)– biOasis Technologies, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application titled “Use of P97 as an Enzyme Delivery System for the Delivery of Therapeutic Lysosomal Enzymes,” US Patent Application Number 12/729,792. The Notice of Allowance is… Read more »

  • Dec. 14, 2012 biOasis Technologies Year in Review 2012

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) today is pleased to provide a 2012 year in review. biOasis has come a long way in 2012. The company has enjoyed a steady, measured progression towards its goals in the execution of its science and business objectives. Through 2012 the company developed a powerful network of highly… Read more »

  • Dec. 3, 2012 biOasis Enters Into a Research Collaboration Agreement with UCB

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) announced today that it has entered into a research collaboration agreement with Brussels, Belgium-based UCB (Euronext Brussels: UCB), to evaluate biOasis’s Transcend technology in the area of the delivery of therapeutic compounds to the brain. In connection with this agreement, biOasis will conduct certain experiments to provide UCB… Read more »